Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -53.26% is 63% above its 5-year average of -143.56%, near the high end of its 5-year range (-385.93%–-23.03%).
113.17% below its 12-month average of -24.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -13.49%.
RETURN ON ASSETS (ROA)
-53.26%
RETURN ON ASSETS (ROA) AVG TTM
-24.98%
RETURN ON ASSETS (ROA) AVG 3Y
-43.10%
RETURN ON ASSETS (ROA) AVG 5Y
-143.56%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-113.17%
CURRENT VS 3Y AVG
-23.56%
CURRENT VS 5Y AVG
+62.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-65.20%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$118.83M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$119.83M
Return on Assets (ROA)
-110.24%
TTM Avg
-77.16%
3Y Avg
-67.85%
5Y Avg
-53.38%
Market Cap
$118.37M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
Market Cap
$118.07M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$120.92M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$120.22M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$121.23M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$115.53M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$114.39M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.83M | -53.26% | -24.98% | -43.10% | -143.56% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.83M | -110.24% | -77.16% | -67.85% | -53.38% |
| BGM Group Ltd. (BGM)vs › | $118.37M | -4.60% | -3.66% | -5.21% | -1.02% |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.07M | -49.93% | -95.40% | -72.70% | -57.07% |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | -1.70% | -35.34% | -51.03% | -36.99% |
| Cibus, Inc. (CBUS)vs › | $120.22M | -31.33% | -56.73% | -59.49% | -64.55% |
| Seer, Inc. (SEER)vs › | $121.23M | -26.48% | -24.24% | -21.83% | -17.99% |
| Coya Therapeutics, Inc. (COYA)vs › | $115.53M | -0.05% | -38.03% | -60.31% | -59.32% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.39M | -134.18% | -145.83% | -164.39% | -180.40% |
| Genelux Corporation (GNLX)vs › | $114.34M | -128.96% | -127.49% | -112.64% | -129.28% |
ROA
-53.3%
ROE
-57.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -26.85% |
| 2024-12-31 | -23.12% |
| 2023-12-31 | -99.42% |
| 2022-12-31 | -23.03% |
| 2021-12-31 | -385.93% |
| 2020-12-31 | -303.02% |
| 2019-12-31 | -1816.67% |
